Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Cymbalta“
Suchtreffer
Begriffe & Kennungen
Cymbalta
Eintrag öffnenCymbalta · 4.1 Therapeutic indications · 1
Eintrag öffnenCymbalta · 4.3 Contraindications · 1
Eintrag öffnenCymbalta · 4.3 · Concomitant use of Cymbalta with nonselective, irreversible monoamine oxidase inhibitors (MAOIs) is contraindi
Eintrag öffnenCymbalta · 4.3 · Cymbalta should not be used in combination with fluvoxamine, ciprofloxacin or enoxacin (i.e. potent CYP1A2 inh
Eintrag öffnenCymbalta · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenCymbalta · 4.3 · Liver disease resulting in hepatic impairment (see section 5.2).
Eintrag öffnenCymbalta · 4.3 · Severe renal impairment (creatinine clearance <30 ml/min) (see section 4.4).
Eintrag öffnenCymbalta · 4.3 · The initiation of treatment with Cymbalta is contraindicated in patients with uncontrolled hypertension that c
Eintrag öffnenCymbalta · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenCymbalta · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenCymbalta · 4.5 · 7 substrate, were not significantly affected by co-administration with duloxetine (60 mg twice daily).
Eintrag öffnenCymbalta · 4.5 · Anticoagulants and antiplatelet agents: Caution should be exercised when duloxetine is combined with oral anti
Eintrag öffnenCymbalta · 4.5 · CNS medicinal products: The risk of using duloxetine in combination with other CNS-active medicinal products h
Eintrag öffnenCymbalta · 4.5 · Effect of duloxetine on other medicinal products Medicinal products metabolised by CYP1A2: The pharmacokinetic
Eintrag öffnenCymbalta · 4.5 · Effects of other medicinal products on duloxetine Antacids and H2 antagonists: Co-administration of duloxetine
Eintrag öffnenCymbalta · 4.5 · Inducers of CYP1A2: Population pharmacokinetic analyses have shown that smokers have almost 50% lower plasma c
Eintrag öffnenCymbalta · 4.5 · Inhibitors of CYP1A2: Because CYP1A2 is involved in duloxetine metabolism, concomitant use of duloxetine with
Eintrag öffnenCymbalta · 4.5 · Medicinal products metabolised by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6. When duloxetine was ad
Eintrag öffnenCymbalta · 4.5 · Monoamine oxidase inhibitors (MAOIs): Due to the risk of serotonin syndrome, duloxetine should not be used in
Eintrag öffnen